---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003617"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-07-28T20:12:49+00:00"
generated_at: "2026-07-28T20:14:08.550141+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Entera Bio raises ~$275M in private placement for phase 3 osteoporosis trial; BVF gets board seats

## Summary
- Raised ~$275M via private placement of 122.96M shares and 11.84M pre-funded warrants at $2.04/share.
- Proceeds to fund phase 3 registrational study of EB613 for postmenopausal osteoporosis and working capital.
- BVF Partners (lead investor) gets right to designate two board directors, subject to ownership thresholds.
- Two current independent directors (Haya Taitel and Yonatan Malca) to resign or not stand for reelection as part of succession plan.
- Company to seek shareholder approval for equity plan increase and executive grants at special meeting in Q4 2026.

## SEC filing metadata
- accession: 0001178913-26-003617
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-07-28T20:12:49+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/0001178913-26-003617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/zk2635734.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003617
- JSON: https://secwatch.observer/filing/0001178913-26-003617.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003617.txt

## Key facts
- Executive change
  Haya Taitel departed as Director at Entera Bio Ltd..
  - Action: resign or not stand for reelection
  - Role: Director
  source text: Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/0001178913-26-003617-index.htm
- Executive change
  Yonatan Malca departed as Director at Entera Bio Ltd..
  - Action: resign or not stand for reelection
  - Role: Director
  source text: Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/0001178913-26-003617-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.